The treatment of patients with melanoma is undergoing a paradigm shift. In October 2023, the FDA approved nivolumab (Opdivo; Bristol Myers Squibb) for patients 12 years and older with completely resected stage IIB/C melanoma. 1 This recent approval is considered a groundbreaking development for patients with advanced melanoma.
Wide local excision of advanced melanoma is one of the most important ways to remove a tumor. 2.3 With this surgery there is a risk of microscopic invasion of cancer cells, and there may be a risk of recurrence of the disease, but adjuvant therapy can help reduce the risk. 2 Although ...
